D-003: Antiplatelet therapy treatment of lipoprotein disorders

Drugs of the Future

Volumn 29, Issue 8, 2004, Pages 773-786

  Mas R ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

1 DOTRIACONTANOIC ACID; 1 HENTRIACONTANOIC ACID; 1 HEPTACOSANOIC ACID; 1 HEXACOSANOIC ACID; 1 HEXATRIACONTANOIC ACID; 1 NONACOSANOIC ACID; 1 OCTACOSANOIC ACID; 1 TETRATRIACONTANOIC ACID; 1 TRIACONTANOIC ACID; 1 TRITRIACONTANOIC ACID; ACETYLSALICYLIC ACID; ALIPHATIC CARBOXYLIC ACID; CARBON TETRACHLORIDE; CHOLESTEROL; D 003; DICOUMAROL; DRUG METABOLIZING ENZYME; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENALINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PARACETAMOL; PLANT EXTRACT; POLICOSANOL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARACHIDONIC ACID METABOLISM; ARTERY INTIMA PROLIFERATION; ARTERY THROMBOSIS; ARTICLE; ASTHENIA; ATHEROSCLEROSIS; BLEEDING TIME; BLOOD CLOTTING TIME; BULIMIA; CHEMICAL COMPOSITION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; COLLAGEN METABOLISM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DISTRIBUTION; DRUG ISOLATION; DRUG MEGADOSE; FOAM CELL; GASTRITIS; GINGIVA BLEEDING; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; INFLUENZA; INSOMNIA; LIPID PEROXIDATION; LIPOPROTEIN DEFICIENCY; LIVER HOMOGENATE; LONG TERM EXPOSURE; MOLECULAR WEIGHT; NONHUMAN; OSTEOLYSIS; OVARIECTOMY; PLEIOTROPY; POLYURIA; RABBIT; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; STOMACH PH; SUGARCANE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS PREVENTION;

EID: 6344291874     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2004.029.08.828449     Document Type: Article

References (93)

1. Murray, C.J.L., López, A.D. Alternate projections of mortality and disability by cause 1990-2020. Global Burden Disease Study. Lancet 1997, 349: 1498-504.
2. World Health Organization. World Health Report 1998: Life in the 21st Century - A Vision of All Geneva, World Health Organization, 1998, Switzerland.
3. Sans, S., Kesteloot, H., Kromhout, D. The burden of the European Society of Cardiovascular Mortality and Morbidity in Europe Task Force of the European Society of Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997, 18: 1231-48.
4. Expert Panel of Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA - J Am Med Assoc 2001, 285: 2486-97.
5. Gotto, A.M., Assman, G., Carmena, R., Davignon, J. et al. The ILIB Lipid Handbook for Clinical Practice. Blood Lipids and Coronary Heart Disease. Second Edition International Lipid Information Bureau (ILIB), New York, 2000.
6. Wood, D. European and American recommendations for coronary heart disease prevention. Eur Heart J 1998, 19(Suppl. A): A12-9.
7. Falk, E., Fernández-Ortiz, A. Role of thrombosis in atherosclerosis and its complications. Am J Cardiol 1995, 75: 1B-7B.
8. Haller, H. Endothelial function: General considerations. Drugs 1997, 53(Suppl. 1): 1-10.
9. Luscher, T.F., Barton, M. Biology of the endothelium. Clin Cardiol 1997, 20(11, Suppl. 2): II-3-10.
10. Shah, P.K. Plaque disruption and coronary thrombosis: New insights into pathogenesis and prevention. Clin Cardiol 1997, 20(11, Suppl. 2): II-38-44.
11. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention trial results. I. Reduction in the incidence of coronary heart disease. JAMA - J Am Med Assoc 1984, 251: 351-64.
12. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention trial results. II. The relationship of reduction in the incidence of coronary heart disease to cholesterol-lowering. JAMA - J Am Med Assoc 1984, 251: 365-74.
13. Frick, M.H., Elo, O., Happa, K. et al. Helsinki Heart Study: Primary prevention with gemfibrozil in middle-aged men with dyslipidemia. New Engl J Med 1987, 317: 1237-45.
14. Anderson, K.M., Wilson, P.W.F., Odell, P.M. et al. An updated coronary risk profile. A statement for health professionals. Circulation 1991, 83: 356-62.
15. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4 444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344: 1383-9.
16. Sacks, P.M., Pfeffer, M.A., Moyé, L.A. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med 1996, 335: 1001-9.
17. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl J Med 1998, 339: 1349-57.
18. Shepherd, S., Cobbe, S.M., Ford, I., Isles, G.G., Lorimer, A.R., Macfarlane, P.W., McKillop, J.H., Packard, C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med 1995, 333: 1301-7.
19. Downs, J.R., Clearfield, M., Weiss, S. et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA - J Am Med Assoc 1998, 279: 1615-22.
20. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial. Lancet 2002, 360: 7-22.
21. Shepherd, J., Blauw, G.J., Murphy, M.B. et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomized controlled study. Lancet 2002, 360: 1623-30.
22. Pearson, T.A., Marx, H.J. The rapid reduction in cardiac events with lipid-lowering therapy: Mechanisms and implications. Am J Cardiol 1993, 72: 1072-3.
23. Corsini, A., Bernini, F., Quarato, P. et al. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Cardiology 1996, 87: 458-68.
24. Graw, A. Can the clinical efficacy of the HMG CoA reductase inhibitors be explained solely by their effects on LDL-cholesterol? Atherosclerosis 1996, 125: 267-9.
25. Delanty, N., Vaughan, C.J. Vascular effects of statins in stroke. Stroke 1997, 28: 2315-20.
26. Bellosta, S., Ferri, N., Arnaboldi, L. et al. Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care 2000, 23(Suppl. 2): B72-6.
27. Corsini, A., Pazzucconi, F., Arnaboldi, L. et al. Direct effects of statins on the vascular wall. J Cardiovasc Pharmacol 1998: 31: 773-8.
28. Davignon, J. The pleiotropic effect of drugs affecting lipid metabolism. In: Atherosclerosis XI, 1998. Proceedings of the XIth International Symposium on Atherosclerosis (Oct 5-8, Paris) 1997, 63-77.
29. Shepherd, J. Fibrates and statins in the treatment of hyperlipidaemia: An appraisal of their efficacy and safety. Eur Heart J 1995, 16: 5-13.
30. Farnier, J.A., Gotto, A.M. Choosing the right lipid-regulating agent. Drugs 1996, 52: 649-61.
31. Baker, S.K., Tarnopolsky, M.A. Statin myopathies: Pathophysiologic and clinical perspectives. Clin Invest Med 2001, 24: 258-72.
32. Gaist, D., García, A., Huerta, C. et al. Lipid-lowering drugs and risk of myopathy: A population based follow-up study. Epidemiol 2001, 12: 565-9.
33. Pasternak, R.C., Smith, S. Jr., Bairey-Merz, C.N. et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002, 40: 567-72.
34. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ - Br Med J 1994, 308: 81-106.
35. Cairns, J.A., Lewis, H.D. Jr., Meade, T.W., Sutton, G.C., Theroux, P. Antithrombotic agents in coronary artery disease. Chest 1995, 108(4, Suppl.): 380S-400S.
36. Sherman, D.G., Dyken, M.L. Jr., Gent, M., Harrison, M.J.G., Hart, R.G., Mohr, J.P. Antithrombotic therapy for cerebrovascular disorders. An update. Chest 1995, 108(4, Suppl.): 444S-56S.
37. Schafer, A. Antiplatelet therapy. Am J Med 1996, 101: 199-209.
38. Patrono, C., Coller, B., Dalen, J.E., FitzGerald, G.A., Fuster, V., Gent, M., Hirsch, J., Roth, G. Platelet-active drugs: The relationships among dose, effectiveness, and side effects. Chest 2001, 119(1, Suppl.): 39S-63S.
39. Awtry, E.H., Loscalzo, J. Aspirin. Circulation 2000, 101: 1206-8.
40. Hassan, M., Amonkar, M. Aspirin for primary and secondary prophylaxis of cardiovascular disease. Curr Ther Res 2001, 62: 676-90.
41. McTavish, D., Faulds, D., Goa, K.L Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs 1990, 40: 238-59.
42. Coukell, A.J., Markham, A. Clopidogrel. Drugs 1997, 54: 745-50.
43. The CAPRIE Study Group. A randomized, blinded, trial of Clopidogrel versus aspirin in patients at high risk of ischemic events (CAPRIE). Lancet 1996, 348: 1329-39.
44. Tanemoto, K., Kanaoka, Y., Kuinose, M. Assessment of antithrombotic agents using the platelet aggregation test. Curr Ther Res 2000, 61: 798-806.
45. Gonzáles Bravo, L., Marrero Delange, D., Laguna Granja, A., Mas Ferreiro, R.M., De Lourdes Arruzazabala Valmaña, M., Carbajal Quintana, D., Cora Medina, M., Menendez Soto Del Valle, R., (Laboratorios Dalmer). Mixture of primary fatty acids obtained from sugar cane wax. WO 9843631.
46. Méndez Antolín, E., Marrero Delange, D., González Canavaciolo, V., Laguna Granja, A. CG determination of long chain fatty acids that compose D003 in 5-mg film-coated tablets. J Pharm Biomed Anal 2003, 31: 613-20.
47. Méndez Antolín, E., Marrero Delange, D., González Canavaciolo, V., Tejeda Díaz, Y, Sierra Pérez, R., Cora Medina, M. Validation of a gas Chromatographic method for determining fatty acids that compose D003 in 10 mg film-coated tablets. Farmaco 2004, 59: 543-7.
48. Gámez, R., Mendoza, S., Más, R., Mesa, R., Castaño, G., Rodriguez, B., Marrero, D. Dose-dependent cholesterol-lowering effects of D-003 on normocholesterolemic rabbits. Curr Ther Res 2000, 61: 460-8.
49. Mendoza, S., Gámez, R., Noa, M., Más, R., Castaño, G., Mesa, R., Mesa, M., de Armas, M. The effects of D-003 and policosanol on the lipid profile and endothelemia cells in normocholesterolemic rabbits. Curr Ther Res 2001, 62: 209-20.
50. Mas, R. Policosanol. Drugs Fut 2000, 25: 569-86.
51. Gâmez, R., Mendoza, S., Mas, R., Noa, M., Arruzazabala, L., Carbajal, D., Castãno, G., Goicochea, E., Mesa, M., Mendoza, N. Comparison of the cholesterol-lowering effects and toxicity of D-003 and lovastatin on normocholesterolemic rabbits. Drugs R&D 2003, 4: 219-29.
52. Mendoza, S., Gamez, R., Mas, R., Goicochea, E. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits. Int J Tissue React 2003, 25: 81-9.
53. Gámez, R., Más, R., Noa, M., Menendez, R., Garcia, H., Gonzalez, J., Ferez, Y., Goicochea E. Effects of chronic administration of D-003, a mixture of sugar cane wax high molecular weight acids, in beagle dogs. Drugs Exp Clin Res 2004, 30: 75-88.
54. Menéndez, R., Más, R., Amor, A.M., Rodeiros, I., Gonzalez, R.M., Alfonso, J.L. Inhibition of cholesterol biosynthesis in cultured fibroblasts by D-003, a mixture of very long chain saturated fatty acids. Pharmacol Res 2001, 44: 299-304.
55. Kroon, P.A., Hand, K.M., Huff, J.W., Alberts, A.W. The effects of mevinolin on serum cholesterol levels of rabbits with hypercholesterolemia. Atherosclerosis 1982, 44: 41-8.
56. Chao, Y.S., Kroon, P.A., Yamin, T.T. et al. Regulation of hepatic receptor-dependent degradation of LDL by mevinolin in rabbits with hypercholesterolaemia induced by a wheat starch-casein diet. Biochim Biophys Acta 1983, 754: 134-41.
57. Menéndez, R., Más, R., Pérez, J., Gonzalez, R.M., Jimenez, S. Oral administration of D-003, a mixture of very long chain saturated fatty acids, prevents casein-induced endogenous hypercholesterolemia in rabbits. Can J Physiol Pharmacol 2004, 82: 22-9.
58. Aviram, M. Macrophages, LDL oxidation and atherosclerosis. In: Atherosclerosis XI, 1998. Proceedings of the XIth International Symposium on Atherosclerosis (Oct 5-9, Paris) 1997, 483-92.
59. Menéndez, R., Mas, R., Amor, A.M., Ledon, N., Perez, J., Gonzalez, R.M., Rodeiro, I., Zayas, M., Jimenez, S. Inhibition of rat lipoprotein lipid peroxidation by the oral administration of D-003, a mixture of very long chain saturated fatty acids. Can J Physiol Pharmacol 2002, 80: 13-21.
60. Molina, V., Arruzazabala, M.L., Carbajal, D., Más, R., Valdés, S. Antiplatelet and antithrombotic effect of D003. Pharmacol Res 2000, 42: 137-43.
61. Gámez, R., Mas, R., Noa, M., Menendez, R., Garcia, H., Gonzalez, J., Perez, Y., Goicochea, E. Six-month toxicity study of oral administration of D-003 in Sprague Dawley rats. Drugs R&D 2002, 2: 375-86.
62. Arruzazabala, M.L., Molina, V., Carbajal, D., Mas, R. D-003 and warfarin on the bleeding time and venous thrombosis experimentally induced in rats. J Med Food 2004, 7: 260-3.
63. Molina, V., Arruzazabala, M.L., Carbajal, D., Más, R. D-003, a new compound with effects on arachidonic acid metabolites. Prostaglandins Leukot Essent Fatty Acids 2002, 67: 19-24.
64. Molina, V., Arruzazabala, M.L., Carbajal, D., Más, R. Synergistic effect of D-003 and aspirin on experimental thrombosis model. Prostaglandins Leukot Essent Fatty Acids 2003, 68: 305-10.
65. Noa, M., Mas, R., Mendoza, N. et al. Effects of D-003 on foam cells induced with carrageenan in experimental models. Rev CNIC Cien Biol 2004, 36: in press.
66. Noa, M., Mas, R., Mendoza, N. et al. Effects of D-003 on smooth muscle cell proliferation in cuffed rabbits. Data on file.
67. Carbajal, D., Noa, M., Molina, V., Arruzazabala, M.L., Más, R., Mendoza, S., González, J. Effect of D-003 on isoproterenol-induced myocardial necrosis in rats. J Med Food 2003, 6: 13-8.
68. Carbajal, D., Arruzazabla, M.L., Noa, M. et al. Protective effect of D-003 on experimental spinal cord ischemia in rabbits. Prostaglandins Leukot Essent Fatty Acids 2004, 70: 1-6.
69. 4C-induced liver acute injury in rats. Drugs Exp Clin Res 2003, 28: 177-83.
70. Mendoza, S., Noa, M., Mas, R., Mendoza, N. Effect of D-003, a mixture of high molecular weight primary acids from sugar cane wax, on paracetamol-induced liver damage in rats. Int J Tissue React 2003, 25: 91-8.
71. Russell, R.G., Rogers, M.J., Frith, J.C., Luckman, S.P., Coxon, F.P., Benford, H.L., Croucher, P.I., Shipman, C., Fleisch, H.A. The pharmacology of biphosphonates and new insights into their mechanism of action. J Bone Miner Res 1999, 14(Suppl. 2): 53-65.
72. Fisher, J.E., Rogers, M.J., Halasy, J.M., Luckman, S.P., Hugues, D.E., Masarachia, P.J., Wesolowski, G., Russell, R.G.G., Rodan, G.A., Reszka, A.A. Alendronate mechanism of action: Geranylgeraniol, an intermediate of the mevalonate pathway, prevents inhibition of osteoclasts formation, bone resorption and kinase activation in vitro. Proc Natl Acad Sci USA 1999, 96: 133-8.
73. Noa, M., Más, R., Mendoza, S., Gamez, R., Mendoza, N. Effects of D-003, a mixture of high molecular weight aliphatic acids from sugarcane wax, on bones of ovariectomized rats. Drugs Exp Clin Res 2004, 30: 35-41.
74. Gámez, R., Rodeiro, I., González, J. et al. Effects of D-003 on hepatic microsomal metabolizying enzymes. J Med Food 2004, in press.
75. Menéndez, R., Marrero, D., Méndez, E. et al. Plasma levels of octacosanoic acid after endogenous dosing with D-003 to rabbits. Rev CNIC Cien Biol 2004, 36: in press.
76. Menéndez, R., Mas, R., Pérez, Y. et al. Pharmacokinetic study of 3H-octacosanoic acid in male rats. Rev CNIC Cien Biol 2004, 36: in press.
77. Kabir, Y., Kimura, S. Biodistribution and metabolism of orally administered octacosanol in rats. Ann Nutr Metab 1993, 37: 33-8.
78. Gámez, R., Más, R., Noa, M. et al. Acute and subchronic oral toxicity of D-003 in rats. Toxicol Lett 2000, 118: 31-41.
79. Gámez, R., Más, R., Noa, M. et al. Acute toxicology of D-003 in rabbits. Rev CNIC Cien Biol 2004, 36: in press.
80. Gámez, R., Rodeiro, I., Fernández, I., Acosta, P. Preliminary evaluation of the cytotoxic and genotoxic potential of D-003: Mixture of very long chain aliphatic acids. Teratog Carcinog Mutag 2002, 22: 175-81.
81. Gámez, R., Gonzaĺez, J.E., Rodeiro, I., Fernández, I., Alemán, C., Rodríguez, M.D., Acosta, P.C., García, H. In vivo genotoxic evaluation of D-003, a mixture of very long chain aliphatic acids. J Med Food 2001, 4: 85-91.
82. González, J.E., Gámez, R., Rodeiro, I. et al. Study on the genotoxic effect of D-003 in SD rats using alkaline electrophoresis of individual cells in gel (pilot study). Rev CNIC Cien Biol 2004, 35: 125-7.
83. Rodríguez, M.D., Gámez, R., González, J.E., García, H., Acosta, C.P., Goicochea, E. Lack of developmental toxicity of D-003: A mixture of long-chain fatty acids in rats. Food Chem Toxicol 2003, 41: 89-93.
84. Rodríguez, M.D., González, J.E., García, H. et al. Teratogenesis study of D-003 in the rabbit. Data on file.
85. Gámez, R., Mas, R., Noa, M. et al. Carcinogenesis study of D-003 in Sprague Dawley rats: Partial report of a 1-year study. Rev CNIC Cien Biol 2004, 36: in press.
86. Schlede, E., Mischke, U., Diener, W., Kayser, D. The international validation study of the acute toxic Class method (oral). Arch Toxicol 1995, 69: 659-70.
87. Castaño, G., Mas, R., Fernãndez, L. et al. Assessment of the effects of D-003, a new antiplatelet and hypocholesterolemic compound on healthy volunteers: A phase I clinical study. Drugs R&D 2002, 3: 337-48.
88. Arruzazabala, M.L., Carbajal, D., Mas, R., Molina, V., Castãno, G., Gãmez, R. Effects of D-003, a new compound purified from sugar cane wax, on platelet aggregation in healthy volunteers: A randomized, double-blinded clinical study. Clin Drug Invest 2003, 23: 107-18.
89. Castaño, G., Menéndez, R., Más, R., Lédon, N., Fernández, J., Pérez, J., González, R.M., Lezcay, M. Effects of D-003 on lipid profile and lipid peroxidation in healthy volunteers. Clin Drug Invest 2003, 23: 193-203.
90. Arruzazabala, M.L., Molina, V., Carbajal, D. et al. Effects of one month treatment with D-003, a mixture of very long chain fatty acids purified from sugar cane wax, on platelet aggregation in healthy volunteers: A double-blinded, placebo-controlled clinical trial. Rev CNIC Cien Biol 2004, 36: in press.
91. Arruzazabala, M.L., Molina, V., Carbajal, D. et al. A randomised, double-blinded clinical study of the effects of policosanoic (D-003), a new substance purified from sugar cane wax, on platelet aggregation and plasma levels of arachidonic acid metabolites in healthy volunteers. Int J Pharmacol Clin Res 2004, in press.
92. Castaño, G., Mas, R., Fernández, L. et al. Effects of D-003 (5-40 mg/day) on lipid profile of patients with type II hypercholesterolemia: A phase II clinical study. Clin Drug Invest 2003, 23: 789-802.
93. Menéndez, R., Mas, R., Pérez, Y. et al. Effect of D-003, a mixture of very high molecular weight aliphatic acids purified from sugarcane wax, on serum lipid peroxidation (LPO) markers in elderly. Data on file.